Free Trial

Lantheus Q3 2023 Earnings Report

Lantheus logo
$91.01 +1.72 (+1.93%)
(As of 05:45 PM ET)

Lantheus EPS Results

Actual EPS
$1.29
Consensus EPS
$1.19
Beat/Miss
Beat by +$0.10
One Year Ago EPS
N/A

Lantheus Revenue Results

Actual Revenue
$319.95 million
Expected Revenue
$315.01 million
Beat/Miss
Beat by +$4.94 million
YoY Revenue Growth
N/A

Lantheus Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad)

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.

Lantheus Earnings Headlines

Lantheus Announces Departure of Chief Medical Officer
Forced out of retirement by these trades
You know, I never really intended to get in front of a camera and tell folks about a new market paradigm that I discovered. Even though I have a bright and shiny “resume,” I thought I’d left investing behind forever. And I was more than happy to be a stay-at-home dad… But then I discovered Gamma Pockets… and everything changed
Lantheus Holdings, Inc. (LNTH): A Bull Case Theory
See More Lantheus Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lantheus? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lantheus and other key companies, straight to your email.

About Lantheus

Lantheus (NASDAQ:LNTH) develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

View Lantheus Profile

More Earnings Resources from MarketBeat

Upcoming Earnings